Stay Flexible<br />By Rev Shark<br />RealMoney.com Contributor<br />10/5/2009 8:46 AM EDT <br /><br />"True genius resides in the capacity for evaluation of uncertain, hazardous and conflicting information." <br /><br />-- Winston Churchill <br />After hitting highs two weeks ago, the major indices have been steadily losing momentum. We have had a few similar pullbacks since the big rally began in March, and each time the market not only found its footing fairly quickly but resumed very strong upside momentum. <br /><br />There is no question that we have had some technical deterioration, especially last week, and that means we have to take some defensive action. The bigger question, however, is whether this is just another routine pullback within a massive uptrend or the beginning of a real change in character. Looking for the market to actually top out has been one of the most frustrating and costly approaches you could take for months now. A lot of folks have been skeptical about the economy and firmly believe, as Professor Nouriel Roubini stated this weekend, that "markets have gone up too much, too soon, too fast." <br /><br />The problem for the bears is that they have held that belief for a while now and have been constantly frustrated as the market keeps going. These skeptics have turned into very powerful dip-buyers because they are so sick of being left behind as the market keeps trending higher. A lot of the folks who are buying pullbacks aren't aggressive bulls; they are just tired of being underinvested in a trending market, so they dip their toe in whenever we have a little pullback. <br /><br />Although the technical conditions of the market look shaky after four straight days of decline, it is probably a mistake to write off the dip-buyers who were so tenacious for so long. They may move to the sidelines and take a rest, but they haven't been hit hard enough to give up on what has been an extremely profitable approach for so long. <br /><br />The bulls have two big positives working for them right now. First, earnings season is starting up, and expectations are going to be very high after the very strong reaction to reports in the second quarter. The market went almost straight up after Intel (INTC) kicked off the second quarter with a good report. There was a flood of better-than-expected reports, and we ended up with several weeks of extremely strong momentum. Expectations may turn out to be too high for the third quarter, but market players are likely to be optimistic at first, and they should help us for the next couple weeks. <br /><br />The other big positive driver for this market is liquidity. With interest rates at nearly zero and a huge amount of government stimulus and bailouts at work, there is a lot of cash looking for a place to go, and quite a bit of it is being parked in equities. That has been a huge driving force for this rally, and it isn't going to suddenly end. <br /><br />I believe that the very high levels of liquidity are going to prevent the market from doing a sudden U-turn back down. We may start to see a downtrend develop, but it won't be the inverse of what we saw on the way up. It will be much more gradual, and we will have many rallies and spikes along the way. <br /><br />In summary, the market has some troubling technical aspects, but it has conditions in place that can help support it and even drive further rallies. While we want to be more cautious given the bigger picture, we don't want to be inflexible and close-minded. The market has issues, but there are also positives that will help to hold things aloft. <br /><br />This morning, we have Goldman upgrading big-cap banks Wells Fargo (WFC) and Capital One (COF) , an upgrade of Research In Motion (RIMM) by Needham and some weakness in the dollar that are helping matters. Overseas markets are slightly positive. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: TRID +16.3%, LOCM +7.4% (light volume)... M&A news: OPTV +15.0% (Kudelski commences tender offer to acquire OpenTV for $1.55/share in cash), BRCD +11.6% (Brocade up for sale - WSJ)... Select financial related stocks showing strength: NMR +7.3% (prices the issuance of new shares and a secondary offering of shares), COF +4.7% (raised to Conviction Buy from Buy by Goldman Sachs - DJ), WFC +4.1% (raised to Buy from Neutral by Goldman Sachs - DJ), RBS +4.0% (Standard Chartered, RBS deal breaks down: Report - Economic Times), HIG +3.0%, RF +2.8%, PUK +2.7%, PNC +2.6%, GNW +2.2%, AIG +2.0%, C +2.0%, USB +1.8%, MS +1.7%, JPM +1.7%, BAC +1.6% (BofA to select emergency CEO - WSJ), LYG +1.3%, ING +1.3%, GS +1.1%... Select metals/mining names showing strength: RTP +3.1% (upgraded to Buy from Hold at RBS), GOLD +2.6%, AEM +2.4%, MT +2.1% (Mittal set to quit $20 bln Indian steel project - Financial Times), BBL +1.3%... Select casino related names trading higher: LVS +2.9%, WYNN +2.0%... Other news: DEPO +24.7% (announces positive top-line results from Phase 3 clinical trial of DM-1796 in postherpetic neuralgia; initiated with a Buy at Merriman), AVII +15.4% (receives expanded contract from U.S. Department of Defense to develop its drug candidate for the treatment of Junin virus infection ; AVI BioPharma mentioned positively in Barron's), PPHM +14.3% (reports positive results from Phase II Bavituximab lung cancer trial), MRM +5.9% (light volume; sets quarterly record of $12.5 mln for new orders), MTW +5.7% (still checking), VIP +4.5% (confirms decision by its two major shareholders, Altimo and Telenor, to combine ownership of VimpelCom and Kyivstar under a new company, VimpelCom Ltd), XNPT +4.4% (light volume; Positive Ph. II results for XP13512 reported for subjects with post-herpetic neuralgia), WMS +1.7% (Cramer makes positive comments on MadMoney)... Analyst comments: MTW +7.5% (upgraded to Buy at Deutsche), SYT +3.6% (upgraded to Overweight at Credit Suisse). <br /><br />Allapoole avanevad:<br /><br />General news: FOLD -26.5% (announces preliminary results suggest that treatment with Plicera was generally well tolerated, with no serious adverse events reported; clinically meaningful improvements in key measures of disease were observed; downgraded to Neutral from Overweight at JP Morgan and downgraded to Underperform at Wedbush Morgan), NURO -13.3% (filed for a ~19.03 mln share common stock offering by selling shareholders), SCLN -7.2% (Phase 2 Trial of RP101 in late-stage pancreatic cancer discontinued), VE -1.9% (still checking)... Analyst comments: AMAG -2.8% (downgraded to Hold at Jefferies), AMD -1.9% (downgraded to Mkt Perform at FBR Capital), VLO -1.8% (downgraded to Sell from Hold at Deutsche Bank), RMD -1.0% (downgraded to Hold at Canaccord Adams).